Here comes the oral GLP-1 drug for diabetes — and Novo Nordisk wants to price Rybelsus 'at a similar level as Ozempic'
Novo Nordisk’s priority review voucher on oral semaglutide has paid off. The FDA approval for the GLP-1 drug hit late Friday morning, around six months after the NDA filing.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
